Seeking more compassionate access to psilocybin as an alternative for Canadians suffering from chronic disease, addiction and palliative depression
TheraPsil announced a delegation of patients and medical professionals from across Canada are planning to make their first in-person appearance in Ottawa later this month. They travel to the nation’s capital to seek more compassionate access to psilocybin for Candia adults suffering from palliative depression, addiction, PTSD and chronic disease.
TheraPsil is a non-profit healthcare advocacy coalition with a mission to expand safe, equitable and legal access to psilocybin-assisted therapy for those in medical need. TheraPsil develops and delivers safe, simple and effective protocols for credentialed health professionals and organizations to provide psilocybin-assisted therapy.
In addition to meeting with decision-makers and health organizations, patients and medical professionals will reach out to Parliamentarians to raise awareness about the medical benefits of psilocybin. A meeting will be held to educate the public and recommend a transparent regulatory approach to guide medical access to psilocybin, just as was done for cannabis in 2000.
Dates: Monday, November 28 – 30, 2022
Location: Parliament Hill – Ottawa, Ontario
Special Event: Tuesday, November 29, West Block, Room 225A (5:30 pm – 7:30 pm)
Media, elected officials, staff, sector leaders, patients and healthcare professionals are invited to attend the special event. In addition to TheraPsil representatives, participants will include:
- Healthcare professionals that have prescribed psilocybin as a treatment for patients
- Canadians suffering from chronic disease that have received a medical exemption to possess psilocybin
- Canadians suffering from chronic disease that have been denied legal access to possess psilocybin for medical purposes
- Lawyers representing Canadians that have been denied medical access
More activities will be announced over the coming days.
“With the worsening overdose crisis, pending MAiD expansion and our experience facilitating psilocybin treatment to over 134 patients over the past two years, we hope the federal Health Minister and other elected officials will provide vulnerable Canadians and health professionals with the right to try this effective natural treatment option,” TheraPsil CEO Spencer Hawkswell
For more information message email@example.com